Dupixent (dupilumab, Sanofi/Regeneron) is an interleukin-4 receptor alpha antagonist that blocks signaling of both IL-4 and IL-13 cytokines. As of April 2026, it is approved for nine distinct diseases driven by type 2 inflammation — atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid, and allergic fungal rhinosinusitis — including the most recent expansion of CSU coverage to children as young as 2 years. Over 1.4 million patients have been treated globally.
Coverage is generally strong for the older, well-established indications but prior authorization is required by virtually every commercial plan, most Medicaid programs, and nearly all Medicare Part D plans. This guide is for access teams, prior authorization coordinators, and prescribers who need to navigate Dupixent coverage across payer types.
Short answer
| Dupixent (dupilumab) | |
|---|---|
| Drug class | IL-4 receptor alpha antagonist (IL-4/IL-13 pathway) |
| Manufacturer | Sanofi and Regeneron Pharmaceuticals |
| FDA indications | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, COPD, CSU (adults/adolescents and children 2+), bullous pemphigoid, AFRS |
| Administration | Subcutaneous injection; dosing varies by indication (200 mg or 300 mg Q2W typical) |
| List price (WAC) | ~$4,193/carton (2 injections) as of January 2026 |
| Average retail | ~$5,500/carton |
| Commercial copay | $0 per fill with DUPIXENT MyWay Copay Card (up to $13,000/year) |
| Medicare Part D | Covered; $0-$2,100/year depending on coverage phase |
| Medicaid | Varies by state; PA required by ~80% of Medicaid plans |
| PA required | Yes, virtually all payer types and indications |
| Step therapy | Commonly required (topical therapy failure for AD; ICS/LABA failure for asthma; inhaled combination therapy failure for COPD) |
| Specialty pharmacy | Required by most commercial and Medicare Part D plans |
FDA-approved indications and dosing
Atopic dermatitis (approved March 2017)
- Indicated for adults and pediatric patients 6 months and older with moderate-to-severe atopic dermatitis not adequately controlled with topical prescription therapies or when those therapies are not advisable
- Adults: 600 mg loading dose (two 300 mg injections), then 300 mg every 2 weeks
- Pediatrics: weight-based dosing (200 mg or 300 mg Q2W depending on weight)
- Available as prefilled pens and syringes
Asthma (approved October 2017)
- Indicated as add-on maintenance treatment for patients 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid-dependent asthma
- Not indicated for relief of acute bronchospasm or status asthmaticus
- Adults: 400 mg or 600 mg loading dose, then 200 mg or 300 mg every 2 weeks depending on asthma severity and comorbid conditions (e.g., concomitant moderate-to-severe AD or CRSwNP)
- Pivotal trials: QUEST, VENTURE
Chronic rhinosinusitis with nasal polyps (approved June 2019)
- Indicated for adults with inadequately controlled chronic rhinosinusitis with nasal polyps
- Dosing: 300 mg every 2 weeks
- Used as add-on to standard of care
Eosinophilic esophagitis (approved May 2022)
- Indicated for adults and pediatric patients 12 years and older weighing at least 30 kg with eosinophilic esophagitis
- Adults (>=60 kg): 300 mg every 2 weeks
- Pediatrics: weight-based dosing
Prurigo nodularis (approved September 2022)
- Indicated for adults with prurigo nodularis
- Dosing: 300 mg every 2 weeks
- First FDA-approved treatment specifically for prurigo nodularis
COPD (approved September 2024)
- Indicated as add-on maintenance treatment of adults with inadequately controlled COPD and an eosinophilic phenotype
- Not indicated for relief of acute bronchospasm or COPD acute exacerbations
- Dosing: 300 mg every 2 weeks
- Pivotal trials: BOREAS, NOTUS
Chronic spontaneous urticaria — adults and adolescents (approved April 2025)
- Indicated for adults and adolescents 12 years and older with chronic spontaneous urticaria (CSU) that remains symptomatic despite H1 antihistamine treatment
- Adults: 600 mg loading dose, then 300 mg every 2 weeks
Bullous pemphigoid (approved June 2025)
- Indicated for adults with bullous pemphigoid
- Dosing: 300 mg every 2 weeks
Allergic fungal rhinosinusitis (approved February 2026)
- Indicated for adults and pediatric patients 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery
- First FDA-approved treatment for AFRS
- Dosing: 300 mg every 2 weeks (adults)
CSU in children 2-11 years (approved April 2026)
- Expanded pediatric CSU approval for children 2 to 11 years
- First biologic approved for young children with chronic spontaneous urticaria
- Weight-based dosing
Coverage by payer type
Commercial insurance
Dupixent is covered by most major commercial plans as a specialty-tier medication. Approximately 99% of commercially insured atopic dermatitis patients (6 months and older) are covered for Dupixent. Prior authorization is required by virtually every commercial plan. Approximately 90% of commercial AD patient lives have to fail only 1 or 2 prescription topical treatments before approval.
| Payer | Coverage status | Key requirements |
|---|---|---|
| UnitedHealthcare | Covered; specialty tier | PA required; step therapy applies; 12-month authorization; indication-specific criteria |
| Cigna | Covered; specialty tier | PA required; indication-specific criteria; revised COPD criteria effective November 2025 |
| Aetna (CVS Health) | Covered; specialty tier | PA required; clinical documentation of severity and prior therapy failure |
| Blue Cross Blue Shield | Covered; varies by plan | PA required; diagnosis-specific criteria; step therapy common |
| FEHB (Federal Employee Program) | Covered; specialty tier | PA required for all indications; specific quantity limits by indication and strength; reauthorization every 16 weeks initially, then 12 months |
Specialty pharmacy dispensing is required by most commercial plans. Buy-and-bill is less common.
Medicare Part D
Dupixent is covered under Medicare Part D. The IRA out-of-pocket cap is $2,100 for 2026. DUPIXENT MyWay Patient Assistance Program (PAP) is available for Medicare Part D patients who qualify.
Key 2026 Medicare details:
- $2,100 annual out-of-pocket cap for all Part D drugs
- 25-33% coinsurance for specialty medications depending on coverage phase
- Medicare Prescription Payment Plan (MPPP) allows monthly installment payments instead of lump-sum cost-sharing
- DUPIXENT MyWay PAP provides free medication for qualifying Part D patients
- Approximately 79% of Medicare Part D enrollees pay $0-$100/month for Dupixent
Medicaid
Dupixent is covered by state Medicaid programs with prior authorization required by approximately 80% of Medicaid plans. PA criteria mirror commercial requirements with additional state-specific documentation.
| State example | Key requirements |
|---|---|
| Pennsylvania Medicaid | PA required; specialist involvement required; updated January 2026 to add bullous pemphigoid criteria |
| General Medicaid | PA required; prior therapy failure documentation; specialist involvement often required; income-eligible patients may pay nominal copay |
Prior authorization process
Required documentation
| Indication | Required documentation |
|---|---|
| Atopic dermatitis | EASI or IGA scoring, documented topical therapy failure (corticosteroids, calcineurin inhibitors), specialist involvement (dermatologist) |
| Asthma | Eosinophil count (>=150-300 cells/uL, payer-dependent), documented ICS/LABA failure, spirometry data, specialist involvement (pulmonologist/allergist) |
| COPD | Eosinophilic phenotype documentation, exacerbation history, documented inhaled combination therapy failure, specialist involvement |
| CRSwNP | Documented nasal corticosteroid failure, specialist (ENT) involvement, imaging confirmation |
| EoE | Endoscopy-confirmed diagnosis, documented prior therapy failure (PPI, topical steroids, elimination diet), specialist involvement (gastroenterologist) |
| Prurigo nodularis | Clinical diagnosis documentation, prior therapy failure, specialist involvement |
| CSU | Documented H1 antihistamine failure, specialist involvement (dermatologist/allergist) |
| Bullous pemphigoid | Biopsy-confirmed diagnosis, prior therapy failure, specialist involvement |
| AFRS | History of sino-nasal surgery, confirmed AFRS diagnosis, specialist (ENT) involvement |
Reauthorization requirements
- Initial authorization: Typically 12-16 weeks depending on payer
- Reauthorization: Documentation of maintained or improved clinical response; most payers reauthorize for 12 months after initial response is confirmed
- FEHB: Reauthorization every 16 weeks initially, then every 12 months
- UnitedHealthcare: 12-month authorization period
Common denial reasons and solutions
| Denial reason | Solution | Required documentation |
|---|---|---|
| Step therapy not met | Document prior therapy failure with specifics | Detailed records of topical corticosteroids, calcineurin inhibitors (AD); ICS/LABA trials (asthma); inhaled combination therapy (COPD); nasal corticosteroids (CRSwNP) |
| Insufficient severity documentation | Submit validated scoring | EASI, IGA, or SCORAD for AD; eosinophil count for asthma/COPD; endoscopy for EoE |
| Missing specialist involvement | Obtain specialist referral or co-sign | Specialist consultation notes, treatment plan from dermatologist, pulmonologist, allergist, gastroenterologist, or ENT |
| Incomplete diagnosis documentation | Submit diagnostic confirmation | Biopsy results (bullous pemphigoid), endoscopy (EoE), imaging (CRSwNP, AFRS), spirometry (asthma/COPD) |
| Quantity limit exceeded | Provide FDA dosing rationale per indication | Prescriber attestation of appropriate dosing per label; weight documentation for pediatric patients |
| Non-formulary drug | Request formulary exception | Medical necessity letter + documentation of alternatives tried or contraindicated |
Cost and patient assistance
Manufacturer savings programs
| Program | Eligibility | Benefit |
|---|---|---|
| DUPIXENT MyWay Copay Card | Commercially insured patients | $0 per fill; covers up to $13,000/year |
| DUPIXENT MyWay Patient Assistance Program (PAP) | Uninsured, underinsured, or Medicare Part D patients who qualify | Free medication |
| DUPIXENT MyWay support | All patients | Injection training, nursing support, insurance navigation; 1-844-DUPIXENT (1-844-387-4936), Mon-Fri 8am-9pm ET |
Cost by insurance type
| Insurance type | Approximate out-of-pocket cost |
|---|---|
| Commercial + DUPIXENT MyWay Copay Card | $0 per fill (~68% of commercially insured patients pay $0-$100/month) |
| Commercial without savings card | Varies by plan (specialty copay or coinsurance) |
| Medicare Part D | $0-$2,100/year depending on coverage phase (~79% of Part D enrollees pay $0-$100/month) |
| Medicare Part D + MyWay PAP | $0 if PAP-eligible |
| Medicaid | Nominal copay or $0 depending on state |
| Uninsured | Full retail (~$5,500/carton) or free via DUPIXENT MyWay PAP if eligible |
Biosimilar landscape
No dupilumab biosimilar has received FDA approval as of May 2026. Several biosimilar candidates are in development — including Formycon's FYB208 and Alvotech's AVT19 — but none have been submitted for or received marketing authorization. Dupixent has no biosimilar competitor at this time. Payers are expected to implement substitution policies when a biosimilar eventually reaches market.
What changed in 2026
- AFRS approval (February 2026): Dupixent became the first FDA-approved treatment for allergic fungal rhinosinusitis, opening a new indication for patients with a history of sino-nasal surgery.
- Pediatric CSU approval (April 2026): Expanded CSU approval to children 2-11 years, making Dupixent the first biologic approved for young children with chronic spontaneous urticaria.
- Biosimilar candidates advancing through development: Formycon's FYB208 and Alvotech's AVT19 are dupilumab biosimilar candidates in development but have not yet received FDA approval. Payers are expected to implement substitution policies when a biosimilar eventually launches.
- Medicare Part D $2,100 OOP cap: Effective January 2026 under the IRA, capping annual Part D out-of-pocket costs for all beneficiaries.
- Pennsylvania Medicaid updated PA criteria (January 2026): Added bullous pemphigoid-specific prior authorization criteria to existing Dupixent policy.
- FEHB updated quantity limits and PA criteria (January 2026): Revised quantity limits by indication and strength; updated PA requirements for newer indications.
- UnitedHealthcare updated COPD and AFRS criteria: Added specific prior authorization criteria for the COPD and AFRS indications.
What to monitor
- Dupilumab biosimilar development and eventual launch: When a biosimilar reaches the market, payers are likely to implement mandatory substitution or step therapy requiring biosimilar use first. Monitor FDA filings, state substitution laws, and payer formulary updates.
- New indication expansions: Sanofi/Regeneron continue to pursue pediatric populations for newer indications. Additional pediatric approvals could expand the covered population.
- Payer formulary positioning relative to competitors: In atopic dermatitis, Dupixent competes with Adbry (tralokinumab), Ebglyss (lebrikizumab), and Nemluvio (nemolizumab). In asthma, it competes with Nucala (mepolizumab), Fasenra (benralizumab), and Tezspire (tezepelumab). Monitor formulary tier placement and step therapy changes.
- IRA negotiation: Dupixent has not yet been selected for Medicare price negotiation, but its spending levels make it a candidate for future rounds. Selection would significantly affect Medicare reimbursement starting in the negotiated price year.
- Prurigo nodularis and bullous pemphigoid payer adoption rates: These newer indications may face tighter PA criteria and lower approval rates initially. Track payer policy updates and denial patterns.
Sources
- FDA, Dupixent prescribing information (February 2026): https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761055s075lbl.pdf
- Drugs.com, Dupixent FDA approval history: https://www.drugs.com/history/dupixent.html
- Regeneron, Dupixent approved for pediatric CSU (April 2026): https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-biologic-medicine-young
- Dupixent HCP website: https://www.dupixenthcp.com/
- Dupixent MyWay patient support: https://www.dupixent.com/support-savings/dupixent-my-way
- Dupixent copay card and insurance savings: https://www.dupixent.com/support-savings/copay-card-insurance
- UnitedHealthcare, Dupixent prior authorization policy: https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-Dupixent.pdf
- Cigna, Dupixent coverage position criteria: https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_420_coverage_positioncriteria_immunologicals_dupixent_pa.pdf
- FEHB, Dupixent pharmacy policy (January 2026): https://www.fepblue.org/-/media/PDFs/Medical-Policies/2026/January/Pharmacy-Policies/Remove-and-Replace/590030-Dupixent-dupilumab.pdf
- Pennsylvania Medicaid, Dupixent prior authorization bulletin (January 2026): https://providers.highmark.com/content/dam/highmark/en/providerresourcecenter/wholecare/documents/pdfs/resource-centers/medical-assistance-bulletins/mab-prior-auth-dupixent.pdf
- OHSU, Dupixent prior authorization guidelines (April 2026): https://www.ohsu.edu/sites/default/files/2026-04/prior-authorization-guidelines-4.1.2026.pdf
- PrescriberPoint, Dupixent therapy information: https://prescriberpoint.com/therapies/dupixent-595f437
- MedFinder, Dupixent access challenges (2026): https://www.medfinder.com/blog/dupixent-shortage-what-providers-prescribers-need-to-know-2026
